Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 11/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29640450 | 0.84 | RXFP1 (0.73) | RXFP1KDM4EKMT2APOLBGAA | |
| SCHEMBL29640436 | 0.82 | RXFP1 (0.62) | RXFP1KMT2APOLBTDP1 | |
| SCHEMBL24770438 | 0.78 | RXFP1 (0.59) | RXFP1KMT2APOLBTDP1 | |
| SCHEMBL29711976 | 0.78 | RXFP1 (0.59) | RXFP1KMT2APOLBTDP1 | |
| SCHEMBL29640476 | 0.76 | RXFP1 (0.59) | RXFP1KMT2APOLBGAATDP1 | |
| SCHEMBL29640494 | 0.74 | RXFP1 (0.54) | RXFP1KMT2APOLB | |
| SCHEMBL29640209 | 0.74 | RXFP1 (0.56) | RXFP1KMT2APOLB | |
| SCHEMBL29640490 | 0.74 | RXFP1 (0.56) | RXFP1KMT2APOLBGAATDP1 | |
| SCHEMBL22966094 | 0.74 | RXFP1 (0.57) | RXFP1KMT2APOLBTDP1 | |
| SCHEMBL29640525 | 0.74 | KDM4E (0.47) | RXFP1KDM4EKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | INSERM - INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (FR) | 2022-12-08 | — | — | US | disclosed |
| EP-4010341-A1 | TRKB POSITIVE ALLOSTERIC MODULATORS | Université de Strasbourg (FR) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | HTT, NTRK2, BDNF | RXFP1 1822/4885KDM4E 1261/4885KMT2A 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.